Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells $20,500.00 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $8.20, for a total value of $20,500.00. Following the completion of the transaction, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $989,699. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Monday, November 11th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $7.82, for a total value of $19,550.00.
• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.10, for a total value of $40,500.00.

Lexeo Therapeutics Stock Down 3.5 %

LXEO stock opened at $6.88 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics, Inc. has a 52-week low of $5.77 and a 52-week high of $22.33. The company has a 50-day moving average of $8.09 and a two-hundred day moving average of $11.28. The stock has a market capitalization of $227.49 million and a price-to-earnings ratio of -2.18.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright increased their price objective on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners dropped their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.80.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares during the period. Values First Advisors Inc. acquired a new stake in Lexeo Therapeutics during the 3rd quarter worth $67,000. MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares during the period. Rhumbline Advisers grew its holdings in Lexeo Therapeutics by 37.3% during the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after acquiring an additional 3,627 shares during the period. Finally, PDT Partners LLC acquired a new stake in Lexeo Therapeutics during the 3rd quarter worth $241,000. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.